docetaxel anhydrous has been researched along with sarcosine in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (sarcosine) | Trials (sarcosine) | Recent Studies (post-2010) (sarcosine) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 1,550 | 69 | 520 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battaglia, M; Bettocchi, C; Ditonno, P; Fanelli, M; Galleggiante, V; Germinario, CA; Larocca, AM; Lucarelli, G; Maiorano, E; Rutigliano, M; Selvaggi, FP; Spilotros, M; Vavallo, A | 1 |
1 other study(ies) available for docetaxel anhydrous and sarcosine
| Article | Year |
|---|---|
Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Castration; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Proportional Hazards Models; Prostatic Neoplasms; Risk Factors; Sarcosine; Taxoids | 2013 |